TITLE:
Advancements in Lynch Syndrome Management: Applying Immunotherapy for Therapeutic Success
AUTHORS:
Abraamyan Feruza, Bobolis Kristie, Gauchan Dron
KEYWORDS:
Lynch Syndrome, Colon Cancer, Genetics, Immunotherapy, Dostarlimab
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.14 No.4,
April
26,
2024
ABSTRACT: Lynch syndrome is the fourth most common cancer in the United States, with an early age of onset and poor prognosis. Here, we present a unique case of a patient with progressive colon cancer due to a late diagnosis of Lynch syndrome showing excellent response to immunotherapy. A 59-year-old male with a history of rectal cancer 30 years ago came to the hospital due to a fever and further found a large necrotic colon mass. Biopsy was positive for colorectal cancer; however, due to the size of the tumor, the patient was deemed not a surgical candidate and offered hospice with palliative chemotherapy. Based on further workup, the patient was diagnosed with Lynch syndrome, with colon cancer determined to be responsive to Immunotherapy. He was started on JEMPERLI (Dosterlimab-gxly), and after three cycles of therapy, imaging and PET scan were repeated, showing decreased activity and extent of the tumor—a tremendous success.